SCA
EW icon

Snowden Capital Advisors’s Edwards Lifesciences EW Stock Holding History

Snowden Capital Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$431K Buy
4,765
+2,136
+81% +$179K 0.01% 909
2026
Q1 		$211K Buy
+2,629
New +$217K 0.01% 1200
2025
Q1 		– Sell
-2,755
Closed -$204K – 1220
2024
Q4 		$204K Buy
+2,755
New +$193K 0.01% 1146
2024
Q3 		– Sell
-3,702
Closed -$342K – 1232
2024
Q2 		$342K Buy
3,702
+588
+19% +$52.1K 0.01% 922
2024
Q1 		$298K Sell
3,114
-16
-0.5% -$1.34K 0.01% 960
2023
Q4 		$239K Sell
3,130
-2,414
-44% -$168K 0.01% 1014
2023
Q3 		$384K Sell
5,544
-41,646
-88% -$3.35M 0.02% 762
2023
Q2 		$4.45M Buy
47,190
+5,514
+13% +$479K 0.16% 173
2023
Q1 		$3.45M Sell
41,676
-651
-2% -$51.2K 0.13% 197
2022
Q4 		$3.16M Sell
42,327
-7,932
-16% -$611K 0.13% 195
2022
Q3 		$4.15M Buy
50,259
+1,717
+4% +$165K 0.19% 137
2022
Q2 		$4.62M Buy
48,542
+7,094
+17% +$734K 0.21% 125
2022
Q1 		$4.88M Buy
41,448
+38,230
+1,188% +$4.29M 0.2% 140
2021
Q4 		$416K Sell
3,218
-3,371
-51% -$393K 0.02% 489
2021
Q3 		$746K Buy
6,589
+187
+3% +$21.3K 0.04% 432
2021
Q2 		$663K Sell
6,402
-3,152
-33% -$297K 0.03% 463
2021
Q1 		$799K Buy
9,554
+55
+0.6% +$4.65K 0.05% 388
2020
Q4 		$867K Sell
9,499
-286
-3% -$23.7K 0.06% 326
2020
Q3 		$781K Buy
9,785
+2,705
+38% +$211K 0.06% 300
2020
Q2 		$489K Sell
7,080
-3,531
-33% -$251K 0.04% 380
2020
Q1 		$667K Buy
10,611
+6,153
+138% +$444K 0.07% 296
2019
Q4 		$347K Sell
4,458
-60
-1% -$4.68K 0.03% 456
2019
Q3 		$331K Sell
4,518
-60
-1% -$4.21K 0.03% 408
2019
Q2 		$282K Sell
4,578
-396
-8% -$23.9K 0.03% 421
2019
Q1 		$317K Sell
4,974
-2,871
-37% -$164K 0.03% 392
2018
Q4 		$401K Buy
7,845
+234
+3% +$11.8K 0.05% 326
2018
Q3 		$442K Buy
7,611
+2,730
+56% +$134K 0.05% 331
2018
Q2 		$237K Sell
4,881
-18
-0.4% -$840 0.03% 395
2018
Q1 		$228K Buy
+4,899
New +$213K 0.03% 351

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Snowden Capital Advisors's EW Position: Q2 2026 in Review

Snowden Capital Advisors increased its Edwards Lifesciences (EW) stake by 81% in Q2 2026, buying an estimated $179K and bringing the position to 4,765 shares worth $431K. The position accounts for 0.01% of the portfolio, ranked #909.

Snowden Capital Advisors first reported a position in EW in Q1 2018 and has held it in 29 quarters since. The position peaked at $4.88M in Q1 2022. 1,334 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Snowden Capital Advisors held 4,765 shares of Edwards Lifesciences worth $431K as of Q2 2026.
  • Snowden Capital Advisors bought 2,136 Edwards Lifesciences shares in Q2 2026, an estimated $179K.
  • Edwards Lifesciences made up 0.01% of Snowden Capital Advisors's portfolio in Q2 2026, its #909 holding.
  • Snowden Capital Advisors first reported a position in Edwards Lifesciences in Q1 2018 and has held it in 29 quarters since.
  • Snowden Capital Advisors's Edwards Lifesciences position peaked at $4.88M in Q1 2022.
  • 1,334 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Snowden Capital Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.